menu search

Jasper (jspr) up on fda nod to begin early-stage urticaria study

Jasper (JSPR) announces the FDA clearance to begin the clinical study of briquilimab for chronic spontaneous u...

October 10, 2023, 9:01 am

Jasper therapeutics to present new positive data on briquilimab conditioning in patients with fanconi anemia at the 2023 fanconi anemia research fund scientific symposium

REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on d...

September 21, 2023, 8:00 am

Scratching the surface: allakos' novel take on urticaria

Allakos displays fiscal discipline with YoY reductions in R&D and G&A, suggesting resource reallocation to pivotal assets like lirentelimab. Lirenteli...

September 18, 2023, 2:07 am

Celldex therapeutics presents positive data from barzolvolimab chronic urticaria program at eaaci 2023

– Data updates at EAACI 2023 continue to position barzolvolimab as a potential best-in-class addition to a historically limited treatment landscape ...

June 10, 2023, 2:45 pm

Dupixent® (dupilumab) application for treatment of chronic spontaneous urticaria (csu) in adults and adolescents aged 12 years and older accepted for fda review

More than 300,000 people in the U.S. suffer from CSU that is inadequately controlled by antihistamines TARRYTOWN, N.Y. and PARIS, March 07, 2023 (GLOB...

March 7, 2023, 6:00 am

Celldex therapeutics presents positive data from barzolvolimab phase 1b study in chronic spontaneous urticaria at aaaai 2023

– Rapid, profound and durable responses across multiple dosing groups with favorable safety profile observed—positioning barzolimab as a potential...

February 26, 2023, 2:00 pm

Jasper therapeutics, inc. reports inducement grant under nasdaq listing rule 5635(c)(4)

REDWOOD CITY, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on d...

February 3, 2023, 9:05 pm

Jasper therapeutics announces closing of public offering of common stock and full exercise of underwriters’ option to purchase additional shares

REDWOOD CITY, Calif., Jan. 27, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on d...

January 27, 2023, 6:10 pm

Third harmonic's stock falls 75% after discontinuing clinical trial

Shares of Third Harmonic Bio Inc. tumbled 75% in premarket trading on Thursday after the company said it discontinued the Phase 1b study of its treatm...

December 15, 2022, 8:22 am

Celldex therapeutics announces multiple upcoming presentations of barzolvolimab data at ga²len global urticaria forum (guf) 2022

– Includes oral presentation for 1.5 mg/kg cold urticaria cohort – – Company to host webcast conf...

December 2, 2022, 2:31 pm

Celldex: barzolvolimab plus bispecific antibodies advancement

Proof of concept has been established in using Barzolvolimab in treating Chronic spontaneous urticaria ...

July 14, 2022, 3:32 pm

Celldex (cldx) down on interim data from phase ib study in csu

Celldex (CLDX) posts interim data from the phase Ib study evaluating barzolvolimab in patients with moderate to severe chronic spontaneous ...

July 4, 2022, 1:12 pm

Sanofi-regeneron's dupixent falls short in chronic spontaneous urticaria trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (...

February 18, 2022, 7:11 am

Sanofi-regeneron's dupixent falls short in chronic spontaneous urticaria trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (...

February 18, 2022, 7:11 am

Sanofi-regeneron's dupixent falls short in chronic spontaneous urticaria trial

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have reported disappointing results from the Phase 3 trial of Dupixent (...

February 18, 2022, 7:11 am


Search within

Pages Search Results: